Atypical lipomatous tumor

Summary

Atypical lipomatous tumor (MONDO:0006097) is a cancer and 4 clinical trials. Top therapeutic interventions include betaine, palbociclib, and mirdametinib. A subtype of tumor of adipose tissue — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	atypical lipomatous tumor
Mondo ID	MONDO:0006097
EFO	EFO:1000099
DOID	DOID:5690
NCIT	C6505
UMLS	C1266129
MedGen	266102
Is cancer (heuristic)	yes

Also known as: ALT · Atypical lipoma · lipoma-like liposarcoma · liposarcoma, well differentiated (morphologic abnormality) · superficial well differentiated liposarcoma · well differentiated liposarcoma · well differentiated liposarcoma of superficial soft tissue

Data availability: 22 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › tumor of adipose tissue › atypical lipomatous tumor

Related subtypes (2): lipomatous cancer, benign lipomatous neoplasm

Subtypes (1): inflammatory liposarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06843967	PHASE1/PHASE2	RECRUITING	A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
NCT03073343	Not specified	RECRUITING	A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
NCT04224064	Not specified	RECRUITING	Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
NCT03740789	Not specified	UNKNOWN	Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BETAINE	4	1
PALBOCICLIB	4	1
MIRDAMETINIB	2	1
GLYCINEBETAINE	0	1